Sivelestat can not only reduce the mortality of ALI/ARDS patients within 28-30 days and the incidence of adverse events, shorten the mechanical ventilation time and ICU stays, increase ventilation free days, but also improve the oxygenation index of patients on days 3, which has a good effect on the treatment of ALI/ARDS. These findings need to be verified in large-scale trials.
Keyphrases
- mechanical ventilation
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- end stage renal disease
- intensive care unit
- chronic kidney disease
- newly diagnosed
- respiratory failure
- ejection fraction
- peritoneal dialysis
- prognostic factors
- risk factors
- patient reported outcomes
- coronary artery disease
- cardiovascular events
- blood flow
- lps induced
- combination therapy
- replacement therapy